Anna Rydén Barrenäs

Anna Rydén Barrenäs, PhD, is a seasoned professional in the field of medical science, currently serving as the Nordic Medical Advisor for Rare Diseases at Chiesi Nordic since June 2022. Previous experience includes roles as a Medical Advisor at LEO Pharma from March 2020 to June 2022, and as a Medical Science Liaison for LEO Pharma AB from March 2019 to March 2020. Anna's research background encompasses a postdoctoral position focused on Type 1 Diabetes at Novo Nordisk NNRC and Pacific Northwest Diabetes Research Center from November 2012 to April 2016. As a doctoral candidate at Linköping University, Anna conducted significant research on the immunological profile of Type 1 Diabetes, culminating in a PhD in Pediatric Immunology. Complementing academic pursuits, Anna possesses extensive teaching experience and is an active board member of the Institutional Animal Care and Use Committee at the Novo Nordisk Research Center in Seattle.